Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AIP 304
- Development stage
- Preclinical
- Lead developer
- AIP
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
01
Overview
AIP 304 is a therapeutic radiopharmaceutical candidate under development by Advanced Innovative Partners (AIP) for the treatment of lung cancer. Currently in the preclinical stage, it is designed as a targeted radionuclide therapy to deliver cytotoxic radiation specifically to lung tumor cells. It is likely intended to be used in a theranostic approach alongside AIP 302, the company's diagnostic imaging agent for lung cancer. As a targeted radionuclide therapy, it aims to provide localized treatment while minimizing damage to surrounding healthy tissues.
Beyond the preview
Go deeper on AIP 304.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AIP 304.